TMZ(Temozolomide)
别名: NSC 362856,CCRG 81045,Methazolastone
中文名称:替莫唑胺
目录号:S1237 Purity: 99.99%
此产品请避光密封保存。
TMZ(Temozolomide)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。Temozolomide可诱导凋亡并具有抗肿瘤的活性。
CAS: 85622-93-1
客户使用Selleck的TMZ(Temozolomide)发表文献220篇
- Cell Discov, 2024 10(1):39
- Signal Transduct Target Ther, 2023 10.1038/s41392-023-01666-3
- Nat Nanotechnol, 2022 17(9):1015-1022
- Cell Res, 2021 10.1038/s41422-021-00528-3
- Nature, 2020 580(7804):517-523
- Signal Transduct Target Ther, 2020 22;5(1):44
- J Thorac Oncol, 2020 10.1016/j.jtho.2020.01.012
- J Hematol Oncol, 2018 11(1):32
- Nat Cell Biol, 2018 20(10):1203-1214
- Cell Stem Cell, 2017 20(2):233-246
- Nat Med, 2015 10.1038/nm.3855
- Nat Commun, 2024 15(1):10089
- Adv Sci (Weinh), 2024 11(44):e2402600
- Cell Death Dis, 2024 15(3):205
- Cell Commun Signal, 2024 22(1):532
- Phytomedicine, 2024 136:156241
- NPJ Precis Oncol, 2024 8(1):59
- Biomed Pharmacother, 2024 176:116892
- Cells, 2024 13(7)632
- Int J Pharm, 2024 665:124710
- Biochem Pharmacol, 2024 223:116113
- Cancer Cell Int, 2024 24(1):36
- Cancers (Basel), 2024 16(16)2852
- Heliyon, 2024 10(23):e40806
- BMC Cancer, 2024 24(1):317
- Cancer Biol Ther, 2024 25(1):2321770
- Cancer Biomark, 2024 40(3-4):297-317
- PeerJ, 2024 12:e16691
- Biol Methods Protoc, 2024 9(1):bpae060
- STAR Protoc, 2024 5(2):103090
- J Tradit Complement Med, 2024 14(1):101-108
- bioRxiv, 2024 2024.01.20.576487.
- Nat Commun, 2023 14(1):5913
- Adv Sci (Weinh), 2023 10(3):e2205529
- Theranostics, 2023 13(11):3744-3760
- Genome Med, 2023 15(1):16
- Cancer Res, 2023 83(16):2750-2762
- Proc Natl Acad Sci U S A, 2023 120(6):e2219199120
- Cell Death Discov, 2023 9(1):22
- Cells, 2023 12(20)2498
- Cancer Sci, 2023 114(1):48-62
- Int J Mol Sci, 2023 25(1)130
- Int J Mol Sci, 2023 24(12)9905
- Int J Mol Sci, 2023 24(2)1616
- CNS Neurosci Ther, 2023 29(11):3430-3445
- Cancer Biol Med, 2023 20(5):385-400
- Cancers (Basel), 2023 15(9)2514
- Drug Des Devel Ther, 2023 17:1357-1369
- Front Oncol, 2023 13:1182853
- Clin Orthop Relat Res, 2023 481(3):608-619
- Heliyon, 2023 9(6):e16559
- Biotechnol Bioeng, 2023 120(4):1108-1119
- Oncol Res, 2023 31(3):345-359
- Sci Adv, 2023 9(19):eadd8023
- bioRxiv, 2023 2023.06.22.544406
- bioRxiv, 2023 10.1101/2023.01.16.524069
- FASEB Bioadv, 2023 5(5):211-220
- ACS Appl Nano Mater, 2023 6(15):14191-14203
- Nat Commun, 2022 13(1):3728
- Clin Transl Med, 2022 12(2):e747
- Cell Death Dis, 2022 13(10):861
- Cell Death Dis, 2022 13(2):138
- Oncogene, 2022 41(30):3791-3803
- Phytomedicine, 2022 94:153816
- Brain Stimul, 2022 15(3):843-856
- Front Immunol, 2022 13:834595
- Cell Death Discov, 2022 8(1):438
- Cells, 2022 11(21)3467
- Int J Mol Sci, 2022 23(13)7051
- CNS Neurosci Ther, 2022 10.1111/cns.13821
- Cancers (Basel), 2022 14(12)3015
- Cancers (Basel), 2022 14(19)4910
- Cancers (Basel), 2022 14(14)3548
- Cancers (Basel), 2022 14(8)1897
- J Nat Prod, 2022 85(1):34-46
- Mol Neurobiol, 2022 10.1007/s12035-021-02674-6
- Lab Invest, 2022 10.1038/s41374-022-00779-7
- J Pers Med, 2022 12(2)258
- Front Oncol, 2022 12:888100
- Biomedicines, 2022 10-92164
- Sci Rep, 2022 12(1):12078
- Sci Rep, 2022 12(1):5827
- Dis Model Mech, 2022 dmm.049109
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Toxicol Appl Pharmacol, 2022 451:116180
- BMC Cancer, 2022 22(1):844
- BMC Cancer, 2022 22(1):786
- Toxicol In Vitro, 2022 83:105420
- Biochem Biophys Res Commun, 2022 627:76-83
- Cancer Chemother Pharmacol, 2022 89(3):401-411
- Cancer Chemother Pharmacol, 2022 10.1007/s00280-021-04380-5
- Neuropathology, 2022 10.1111/neup.12824
- Anticancer Drugs, 2022 33(1):e381-e388
- Autophagy, 2021 1-15
- Theranostics, 2021 11(4):1991-2005
- Clin Cancer Res, 2021 clincanres.2092.2021
- J Exp Clin Cancer Res, 2021 40(1):164
- Cancer Res, 2021 canres.0810.2021
- Clin Transl Med, 2021 11(10):e608
- Cancer Immunol Res, 2021 9(12):1383-1399
- Cell Rep, 2021 37(1):109788
- J Pathol, 2021 10.1002/path.5776
- Phytother Res, 2021 10.1002/ptr.7061
- Cancer Gene Ther, 2021 10.1038/s41417-021-00353-1
- Mol Cancer Ther, 2021 10.1158/1535-7163.MCT-21-0126
- Mol Med, 2021 27(1):28
- Front Cell Dev Biol, 2021 9:683038
- Exp Neurol, 2021 347:113907
- Cancers (Basel), 2021 13(22)5620
- Cancers (Basel), 2021 13(20)5114
- Int J Oncol, 2021 59(2)64
- Front Oncol, 2021 11:702983
- Neuropharmacology, 2021 196:108717
- Front Oncol, 2021 11:638802
- Front Oncol, 2021 11:635472
- Sci Rep, 2021 11(1):20338
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Neurochem Int, 2021 147:105051
- Oncol Rep, 2021 45(4)34
- J Biochem Mol Toxicol, 2021 e22848
- J Cancer Res Clin Oncol, 2021 10.1007/s00432-021-03678-4
- Hum Mol Genet, 2021 ddab193
- Hum Mol Genet, 2021 ddab009
- Free Radic Res, 2021 1-22
- Exp Ther Med, 2021 21(2):175
- Am J Transl Res, 2021 13(10):11413-11426
- Nat Commun, 2020 11(1):550
- J Clin Invest, 2020 139542
- J Clin Invest, 2020 134132
- Theranostics, 2020 10(7):3351-3365
- Clin Cancer Res, 2020 clincanres.2585.2020
- J Exp Clin Cancer Res, 2020 39(1):137
- Cancer Res, 2020 canres.132.2020
- EBioMedicine, 2020 59:102971
- Cell Death Dis, 2020 11(10):890
- Cell Chem Biol, 2020 S2451-9456(20)30384-6
- Oncogene, 2020 5
- Mater Sci Eng C Mater Biol Appl, 2020 108:110191
- Fluids Barriers CNS, 2020 2;17(1):37
- Cancer Cell Int, 2020 19;20:58
- Cancer Cell Int, 2020 20:65
- Cancer Cell Int, 2020 20:71
- Mol Cancer Ther, 2020 19(10):2001-2011
- Int J Mol Sci, 2020 21(21)E8353
- J Cell Mol Med, 2020 10.1111/jcmm.15114
- Aging (Albany NY), 2020 29;12(2):1685-1703
- Transl Oncol, 2020 13(1):70-78
- Cell Signal, 2020 71:109598
- Sci Rep, 2020 10(1):3836
- Front Neurosci, 2020 14:598266
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Neuroendocrinology, 2020 3
- PLoS One, 2020 22;15(4):e0231470
- J Cancer Res Clin Oncol, 2020 146(7):1659-1670
- bioRxiv, 2020 10.1101/2020.11.26.400234
- Nat Commun, 2019 10(1):4529
- Cancer Commun (Lond), 2019 39(1):81
- Autophagy, 2019 15(6):1100-1111
- J Pineal Res, 2019 66(3):e12556
- Cell Death Dis, 2019 10(12):881
- Cancer Biol Med, 2019 16(3):606-617
- Pharmaceutics, 2019 11(8)E401
- Cancers (Basel), 2019 11(12)
- Eur J Pharmacol, 2019 852:42-50
- Eur J Pharm Biopharm, 2019 136:156-163
- FASEB J, 2019 33(12):13476-13491
- Endocrinology, 2019 160(11):2600-2617
- J Oncol, 2019 2019:1805841
- Hum Mol Genet, 2019 28(16):2738-2751
- Hum Mol Genet, 2019 10.1093/hmg/ddz152
- Oncol Lett, 2019 18(3):2509-2517
- Mol Imaging, 2019 18:1536012119870899
- Anticancer Res, 2019 39(12):6731-6741
- Nat Commun, 2018 9(1):2494
- J Clin Invest, 2018 128(1):446-462
- Cancer Res, 2018 78(23):6632-6642
- J Control Release, 2018 269:245-257
- Cancer Lett, 2018 433:210-220
- Genome Res, 2018 28(8):1207-1216
- Mol Cancer Res, 2018 16(5):777-790
- Int J Oncol, 2018 52(1):295-304
- Mol Pharm, 2018 15(2):609-618
- Sci Rep, 2018 8(1):7222
- Cell Cycle, 2018 17(10):1199-1211
- Onco Targets Ther, 2018 11:7031-7040
- Cancer Med, 2018 7(4):1404-1415
- J Neurooncol, 2018
- J Pharm Sci, 2018 107(3):922-933
- Oncol Lett, 2018 16(5):5607-5614
- Medicines (Basel), 2018 5(2)
- Neuro Oncol, 2017 20(2):236-248
- Clin Cancer Res, 2017 23(20):6239-6253
- Clin Cancer Res, 2017 23(2):523-535
- Cancer Lett, 2017 386:131-140
- Cell Syst, 2017 4(6-:600-610
- Cell Death Dis, 2017 8(10):e3062
- JCI Insight, 2017 2(24)
- Eur J Med Chem, 2017 127:691-702
- Mol Oncol, 2017 11(2):180-193
- Oncotarget, 2017 8(12):18626-18639
- Oncotarget, 2017 8(18):29865-29886
- Hum Mol Genet, 2017 26(22):4375-4387
- Biochim Biophys Acta Gen Subj, 2017 1861(9):2282-2292
- J Clin Invest, 2016 126(5):1801-14
- Cancer Res, 2016 76(1):139-49
- Mol Cancer Ther, 2016 15(10):2302-2313
- Oncotarget, 2016 7(48):79869-79884
- Oncotarget, 2016 7(43):69961-69975
- Oncotarget, 2016 7(27):41251-41264
- Eur J Pharm Biopharm, 2016 104:7-18
- Neurochem Res, 2016 41(12):3192-3205
- Tumour Biol, 2016 37(8):11443-56
- Radiother Oncol, 2015 116(3):467-72
- PLoS One, 2015 10(11):e0142704
- Clin Cancer Res, 2014 20(6):1555-65
- Cancer Biol Ther, 2014 15(12):1646-57
- Clin Cancer Res, 2013 19(7):1740-7
化学信息&溶解度
分子量 | 194.15 |
分子式 | C6H6N6O2 |
CAS号 | 85622-93-1 |
Smiles | CN1C(=O)N2C=NC(=C2N=N1)C(=O)N |
储存条件(自收到货起) | 3年 -20°C(避光) 粉状 |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 39 mg/mL ( 200.87 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 7 mg/mL Ethanol : Insoluble DMSO : 20 mg/mL ( 103.01 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 39 mg/mL ( 200.87 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 39 mg/mL ( 200.87 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 5 mg/mL Ethanol : Insoluble DMSO : 19 mg/mL ( 97.86 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 3 mg/mL Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
30%PEG300
65%ddH2O
浓度:2mg/ml
(10.30mM)
操作示例:以 1 mL 工作液为例,取50μL40mg/ml的澄清DMSO储备液加到300μL PEG 300中,混合均匀使其澄清;然后继续加入650μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5% DMSO
95% Corn oil
浓度:0.4mg/ml
(2.06mM)
操作示例:以1 mL工作液为例,取50μL 8mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:2mg/ml
(10.30mM)
操作示例:以 1 mL 工作液为例,取50μL40mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
Corn oil
浓度:2mg/ml
(10.30mM)
操作示例:以 1 mL 工作液为例,取50μL40mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。